Im­muno­vant takes on ar­genx, J&J with plans to test FcRn in­hibitor in mul­ti­ple par­al­lel tri­als af­ter PhI win 

Im­muno­vant is gear­ing up to start a slate of mid-stage as well as piv­otal tri­als for its fol­low-on au­toim­mune drug, IMVT-1402, af­ter con­firm­ing what it calls “best-in-class” po­ten­tial in a Phase I healthy vol­un­teer study.

Tues­day’s da­ta up­date — on mul­ti­ple as­cend­ing dos­es of 600 mg each — comes two months af­ter news about the 300 mg co­hort dou­bled Im­muno­vant’s share price $IMVT and spurred a spike in the stock of Roivant $ROIV, which owns a con­trol­ling stake in Im­muno­vant.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER